Protagenic Therapeutic -CW25PTIXWPreferred / convertible
13F holders, Q3 2024 (September 30)3holders −1
0new positions
1sold out
$0.01avg. 13F price*
At the end of Q3 2024, 3 institutions reported holding Protagenic Therapeutic -CW25 (PTIXW) in their 13F filings, down 1 from Q2 2024. 0 opened new positions and 1 sold out. The largest holders were Warberg Asset Management LLC ($2K), Susquehanna International Group, LLP ($420) and GTS Securities LLC ($228).
- Company
- Protagenic Therapeutic -CW25
- CUSIP
- 74365N111
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $1 |
All 13F filers, Q2 2024 → Q3 2024: 20,015 shares bought and 100 shares sold, net +19,915 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Warberg Asset Management LLC | — | No change | 177,196 | $2K |
| Susquehanna International Group, LLP | — | Add +75.2% | 46,615 | $420 |
| GTS Securities LLC | — | No change | 25,300 | $228 |
"% of holder's portfolio" is PTIXW's weight in each manager's 13F, not the share of Protagenic Therapeutic -CW25 the manager owns.